VANCOUVER, Nov. 30 /PRNewswire/ - iCo Therapeutics Inc. announced today
the company's newly-formed Strategic Advisory Team. Team members Dr. Julia
Levy, Dr. George Lasezkay and Richard Glickman will assist iCo's management
team and Board chart the company's strategy for growth and development.
"We are extremely pleased to have such an esteemed group of science and
business advisors helping us to achieve our goals," said Andrew Rae, iCo
President and CEO.
Dr. Julia Levy, co-founder and former President and CEO of QLT Inc., is
currently Executive Chairman of the Scientific Advisory Board at QLT. Under
Dr. Levy's stewardship QLT rose to become one the leading biotech companies
worldwide with the launch of Visudyne in 2000 to treat age-related macular
degeneration. A former microbiology professor at the University of British
Columbia and a Fellow of the Royal Society of Canada, Dr. Levy was selected
Female Entrepreneur of the Year for International Business in 1998 by Canadian
Business magazine, and appointed to the Order of Canada in 2001. She received
a B.A. (Hon.) from the University of British Columbia and a Ph.D. in
experimental pathology from the University of London.
Dr. Lasezkay is a principal in Turning Point Consultants, LLC, a
consultancy group that advises life science companies on strategy and business
development, and he is a former Corporate Vice President of Corporate
Development at Allergan, a global ophthalmology pharmaceutical company. He
also has extensive experience in hospital pharmacy practice, clinical
pharmacokinetics consultation, drug research and pharmacy education.
Dr. Lasezkay earned B.S. Pharmacy and Doctor of Pharmacy degrees from the
State University of New York at Buffalo and a J.D. degree from the University
of Southern California Law Center. He currently serves as a director of
Valentis Inc., Collagenex Pharmaceuticals, Acuity Pharmaceuticals, Sucampo
Pharmaceuticals, and Novagali Pharma, SA.
Mr. Richard Glickman is co-founder, CEO and Chairman of Aspreva
Pharmaceuticals Corporation and has a successful track record raising capital
for pharmaceutical and biopharmaceutical companies, including Stressgen
Biotechnologies Corp., where he served as CEO. Mr. Glickman was the founder
and director of Ontario Molecular Diagnostics, a former director of the
Canadian Genetic Diseases Network and a co-founder of Probtec Corp. where, as
vice-president he established and introduced Canada's first licensed DNA-based
forensic and paternity testing service. Mr. Glickman has received both
Canada's and British Columbia's Top 40 under 40 Awards for entrepreneurs and
was the Ernst & Young 2004 Entrepreneur of the Year recipient for Life
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new conditions
affecting isolated biological environments - areas such as the eye, spinal
cord, or joints - where locally-administered application of these therapies
would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at:
Business Development Contact: Finance/Investor Contact:
Dr. John Clement, CTO Mr. John Meekison, CFO
SOURCE iCo Therapeutics Inc.